Table 2.
Characteristics | Unweighted n | Weighted % (95%-CI) |
---|---|---|
Comorbid conditions |
|
|
History of allergic rhinitis |
678 |
54.5 (50.6-58.3) |
Current allergic rhinitis (in the past year) |
535 |
42.3 (38.6-46.0) |
Current GERD-like symptoms (in the past year) |
522 |
49.6 (45.8-53.4) |
History of AERD |
138 |
14.0 (11.3-17.2) |
History of nasal polyps |
350 |
29.8 (26.5-33.4) |
- among AERD cases |
57 |
36.9 (26.9-48.2) |
- among non-AERD cases |
287 |
28.3 (24.8-32.1) |
History of AERD and nasal polyps (Samter’s triad) |
57 |
5.2 (3.7-7.3) |
Study outcome |
|
|
Any vs. no asthma-related hospitalization/emergency department admission in the past year | 96 | 9.0 (7.1-11.5) |
Weighted prevalence (%) with 95% confidence interval (95%-CI), unweighted count (n). Unknown or missing responses excluded from the analyses. % (n) of missing values for outcome study variable are as follows: any asthma-related hospitalization/emergency department admission in the past year 0.1% (n = 2) missing values. % (n) of missing values for primary independent study variables are as follows: current AR 1.1% (n = 15), current GERS 0.3% (n = 6), and AERD 1.2% (n = 12). Gastroesophageal reflux disease (GERD); acetylsalicylic acid exacerbated respiratory disease (AERD).